The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

OneOncology Speakers Make Case for Community Setting in Research, Value Delivery

December 20th 2021, 1:24am


Duncan Allen, MHA, introduced the audience to the OneR clinical research initiative, and Jeffrey Patton, MD, discussed how the hospital transparency law has bolstered the case for the value of community oncology.

Murine Study Suggests Novel I-O Combo May Be Effective in CRC

September 4th 2021, 10:45am


The murine study, which assessed the combination of foretinib and an anti–PD-1 antibody, found that the regimen enhanced antitumor activity, offering promise in a cancer that has seen less success with immunotherapies than others.

Study Will Collect Patient Preferences for NSCLC Treatments

August 31st 2021, 8:49pm


This study protocol comes amid a paradigm shift in the treatment of advanced-stagen non–small cell lung cancer (NSCLC) following the emergence and uptake of immunotherapy.

Improved Immunotherapy Education Needed for Patients to Grasp Benefits, Risks

August 25th 2021, 1:18pm


Survey responses from patients with advanced cancer revealed that there were gaps in knowledge across various aspects of immunotherapy treatment, including about side effects and curative potential.

Meta-Analysis Highlights Promising Efficacy, Safety of Approved CAR T-Cell Products

August 23rd 2021, 2:30pm


Researchers found the 3 treatments—axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel (liso-cel)—showed promising efficacy and safety results across histological types, although they noted a need for more real-world data to validate the efficacy of liso-cel.

Analysis Offers Longer-Term Safety Profile of CAR T-Cell Therapy for B-ALL

August 22nd 2021, 5:00pm


The findings come from a pooled analysis of the ELIANA and ENSIGN trials, both of which led to the approval of tisagenlecleucel for these patients.

August 2021: Targeted Therapy & Immuno-Oncology

August 17th 2021, 1:47am


Cardinal Health Experts Outline How Research, Regulatory Approaches Can Speed Drug Approval

August 17th 2021, 1:03am


Impact of COVID-19 on Disparities in Cancer Outcome Spans Various Groups of Patients

August 13th 2021, 5:15pm


Recent research showed that patients with Medicaid are more likely than commercially insured patients to have worsened end-of-life experience and that Black patients with breast cancer fare worse than other ethnic groups when it comes COVID-19 outcomes.

Researchers Highlight Delivery of CAR T-Cell Therapy Through Modified AAV

August 11th 2021, 7:30pm


In a preclinical study, researchers were able to show that their modified adeno-associated virus (AAV) vector safely delivered the chimeric antigen receptor (CAR) gene into the host cells and produced enough CAR T cells to cause effective tumor regression and elicit antitumor immunological characteristics in a mouse model of human T-cell leukemia.